Clinical Guidelines for Doxy PEP Bacterial STI Prevention
Tuesday, May 20, 2025
12:15 PM – 12:45 PM
CE: .50 AAPA Category 1 CME
No relevant relationships with ineligible companies to disclose within the past 24 months.
This session will review newly-released clinical guidelines for the use of doxycycline postexposure prophylaxis (doxy PEP) as a biomedical sexually transmitted infection (STI) prevention strategy for selected populations. Incidence of STIs caused by Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum continues to increase in the U.S. Doxy PEP has demonstrated benefit in reducing syphilis, chlamydia, and gonorrhea and represents a new approach to addressing STI prevention. CDC recommends that providers offer persons a prescription for doxy PEP to be self-administered within 72 hours after having oral, vaginal, or anal sex. Doxy PEP should be implemented in the context of a comprehensive sexual health approach, including risk reduction counseling, STI screening and treatment, recommended vaccination, and linkage to HIV PrEP, HIV care, or other services as appropriate.
Learning Objectives:
At the conclusion of this session, participants should be able to:
Discuss the current epidemiology of sexually transmitted infections (STIs) in the U.S.
Identify populations that would benefit most from doxy PEP
Evaluate clinical indications to apply the new guidelines for use of doxy PEP
